LDS/Medical Tests/Cytochrome P450 2E1 (CYP2E1) Genotyping

Cytochrome P450 2E1 (CYP2E1) Genotyping

The cytochrome P450 (CYP450) enzymes metabolize the majority of drugs as well as organic compounds in our body. Most of CYP450 enzyme family members are expressed in the liver. The expression level of different CYP enzymes varies. Some of the highly expressed CYP enzymes in the liver include CYPs 1A2, 3A4, 2C9, 2C8, and 2E1. The expression levels and/or activities of CYPs of each individual are affected by factors like genetic polymorphism, disease condition, and inducing or inhibitory chemicals. Evidence has shown that genetic polymorphisms of different CYP genes, which largely depend on ethnicity, are clinically important regarding drug dosing, drug efficacy, and adverse drug reactions (ADRs).

CYP2E1 is one of the highest expressed CYP proteins in adult liver, although it is undetectable in fetal liver. The expression and enzymatic activity of CYP2E1 is largely variable among individuals, which is largely due to its inducibility. Its expression and activity is regulated at transcriptional, translational, and post-translational levels by its substrates, several hormones, and pathophysiological conditions. The majority of CYP2E1 substrates are small molecules including organic solvents like ethanol and acetone, narcotics like halothane, and drugs like chlorzoxazone and paracetamol. When CYP2E1 oxidizes ethanol, it produces reactive oxygen species that damage liver cells. This has led to some studies that suggest it is the cause of alcoholic liver disease as well as nonalcoholic fatty liver disease.

Only 7 CYP2E1 star alleles have been confirmed to-date, which is far less than many other CYP genes. Among these variants, the 5’-upstream region polymorphisms, *1C and *1D, show greater expression after ethanol induction. Little or no effect on enzyme function was found in most alleles except for the *2 variant. Regarding the function of CYP2E1 in the metabolic activation of carcinogens, studies have shown correlation between altered susceptibility to cancers and different CYP2E1 genetic polymorphisms.

  • Help estimate chemical induced cancer risk and alcohol-related cancers
  • Determining therapeutic strategy for drugs metabolized by CYP2E1
  • Monitor and manage chlorzoxazone and paracetamol therapy
Increased enzyme activity is seen in both \*1C, and \*1D variants. Both have greater induction after alcohol exposure Decreased enzyme activity is seen in genotypes with variant \*2. CYP2E1 drug Substrate: Chlorzoxazone, Dacarbazine, Enflurane, Halothane, Isoflurane, Isoniazid, Sevoflurane, Theophylline, Trimethadione, acetaminophen, isoniazid CYP2E1 drug Inhibitor: Clomethiazole, Diethyldithiocarbamate, Disulfiram, 4-methylpyrazole, Orphenadrine CYP2E1 drug Inducer: Pyrazole, Isoniazid, Ethanol, Acetone

CYP2E1 \*1/\*1 (Normal metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7 days
Liver profile, Acute hepatitis panel (to rule out infectious hepatitis), liver biopsy to assess liver fibrosis, Drug toxicity tests and clinical assessments are recommended for other drugs; other CYP enzymes such as CYP2D6, CYP2C19, and CYP2C9.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login